Yucebio, founded in 2015, is a leading platform in China that offers comprehensive solutions for the diagnosis and treatment of cancer immunology. Their focus is on the development, transformation, and commercialization of products related to the detection of tumor neoantigens. Yucebio boasts a state-of-the-art platform for tumor neoantigen detection and identification, as well as a comprehensive tumor immunology multidimensional detection and research platform.

They also have specialized tumor immunology bioinformatics interpretation databases and real-world research databases. With an internationally recognized research and production quality system and an experienced management team, Yucebio provides clinically accessible medication guidance and dynamic monitoring products for cancer patients. They also offer precise medical solutions for medical institutions and service providers and high-quality companion diagnostics and therapeutic target development services for pharmaceutical companies.

Yucebio has secured five rounds of funding totaling hundreds of millions of RMB since its establishment. They have established a third-party medical testing laboratory and a research and development production base in Jiangsu Province, with business coverage spanning over 40 cities and 400 hospitals. Yucebio has applied for 45 domestic and international patents and obtained 56 software copyrights.

In 2017, in collaboration with Academician Qimin Zhan, they initiated the China Cancer · Ladder Program for real-world research on cancer immunology. Yucebio holds the prestigious accreditations of a national high-tech enterprise and a Shenzhen high-tech enterprise. They are also an Asian company that has joined the International Neoantigen Screening Alliance.

Additionally, they are at the forefront of providing TMB (tumor mutation burden) testing, tumor immunotherapy gene data, and dynamic monitoring of tumor immunotherapy effectiveness. Yucebio's mission is to make cancer immunology more effective, and they strive to become China's leading brand for precision cancer immunotherapy. They uphold values of openness, efficiency, rigor, innovation, and customer-centeredness, always putting their customers first and using market-oriented strategies.

Yucebio's medical testing laboratory, called Yuke Medical Laboratory, is a third-party independent medical testing laboratory approved by the Shenzhen Health Commission. From the beginning, Yuke Medical Laboratory has prioritized quality and built its laboratory quality management system in accordance with international standards such as the College of American Pathologists (CAP) and ISO15189. The laboratory is equipped with advanced gene sequencing platforms, digital PCR platforms, expression analysis platforms, spatial expression analysis platforms, flow cytometry analysis platforms, circulatory proteinomics testing platforms, pathology and immunohistochemistry platforms, and single-cell analysis platforms.

Yuke Medical Laboratory has implemented a fully automated and informationized system from sample reception, sample management, sample preparation, sequencing, bioinformatics analysis, result interpretation to report issuance. They continuously update gene information databases and clinical interpretation databases in real-time, providing high-quality and high-precision clinical testing services, as well as multidimensional and comprehensive medical research services